Qube Research & Technologies LTD Beam Therapeutics Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $91,330 - $140,568	4,304 Added 4.39%	102,359 $2.4 Million
Q1 2024 May 14, 2024	BUY	$23.46 - $45.07 $2.3 Million - $4.42 Million	98,055 New	98,055 $3.24 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $3.45 Million - $5.59 Million	114,568 New	114,568 $3.51 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $560,561 - $1.17 Million	-18,773 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$53.73 - $82.16 $1.01 Million - $1.54 Million	18,773 New	18,773 $1.08 Million
Q4 2021 Feb 01, 2022	SELL	$68.02 - $99.06 $293,506 - $427,443	-4,315 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $138,366 - $219,104	1,640 Added 61.31%	4,315 $375,000
Q2 2021 Aug 13, 2021	SELL	$64.12 - $128.71 $84,061 - $168,738	-1,311 Reduced 32.89%	2,675 $344,000
Q1 2021 May 14, 2021	BUY	$71.28 - $120.75 $284,122 - $481,309	3,986 New	3,986 $319,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.01B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.